(Q38108399)

29 August 2017

Emerging drugs for neuroblastoma (English)

1 reference

29 August 2017

1

1 reference

29 August 2017

Vanessa Segura

2

1 reference

PubMed ID

23692586

29 August 2017

Pablo Berlanga

series ordinal

3

1 reference

PubMed ID

23692586

29 August 2017

language of work or name

English

0 references

publication date

22 May 2013

1 reference

Expert Opinion on Emerging Drugs

29 August 2017

1 reference

29 August 2017

18

1 reference

29 August 2017

2

1 reference

29 August 2017

155-171

1 reference

Epidemiology of childhood cancer

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Neuroblastoma in adults: Incidence and survival analysis based on SEER data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

A proposed staging for children with neuroblastoma.Children's cancer study group A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Chromosome 1p and 11q deletions and outcome in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Focal DNA copy number changes in neuroblastoma target MYCN regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Treatment of high-risk neuroblastoma with anti-GD2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Factors influencing survival in children with recurrent neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Angiogenesis as a target in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Successful antiangiogenic therapy for neuroblastoma with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Targeting ALK in neuroblastoma--preclinical and clinical advancements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Promising therapeutic targets in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Emerging importance of ALK in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Activation of Akt predicts poor outcome in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

The mTOR signalling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Predictors of competing mortality in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Recent advances in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Survival of European children and young adults with cancer diagnosed 1995–2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

Neuroblastoma in adolescents: genetic and clinical characterisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.796927

10.1517/14728214.2013.796927

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23692586